Celgene Corporation

CELG

(NASDAQ)

Industri: Health Care seperator

Sektor: Pharmaceuticals & Biotechnology

$ 89,20 <%= Resources.Global.txtUp %>

Opdateret 25-04-2018

Ændring %	0,07%
Ændring	0,06
Volume	1.438.589
Høj	$ 89,62
Lav	$ 88,13
Åben	$ 89,09
ISIN
Seneste luk	$ 89,14
# af aktier	752,18M
Markedsværdi	67.094M USD

I dag

Market closed

Markedet er lukket, åbner klokken 15:30


Kursudvikling	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år

	89,20	-0,5%	2,3%	-15,2%	-10,8%	-28,8%

Dansk
Engelsk
Fondsbørsmeddelelser

	23 apr	CELG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018

	17 apr	New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel — Factors of Influence, Major Initiatives and Sustained Production

	16 apr	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG

	14 apr	CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

	06 apr	Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action and to the Abrupt Departure of Celgene’s President

	03 apr	SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018

	02 apr	SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq: CELG) To Contact Brower Piven Before The Lead Plaintiff Deadline

	31 mar	CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

	20 mar	Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

	02 feb	Investor Expectations to Drive Momentum within Connecticut Water Service, Datawatch, Cadiz, Celgene, Texas Instruments, and Newfield Exploration — Discovering Underlying Factors of Influence

Flere nyheder

	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år	ÅTD

Konkurrenter

Shire PLC ORD 5P	3.839,00	-3,4%	30,0%	11,6%	9,0%	-16,6%	-1,6%

Bristol-Myers Squibb Company	51,76	0,3%	-18,4%	-19,4%	-15,1%	-3,7%	-15,5%

Johnson & Johnson	126,76	-0,6%	-0,5%	-12,8%	-10,6%	2,6%	-9,3%

Merck & Company Inc (new)	59,63	1,2%	10,3%	-3,9%	-3,8%	-4,9%	6,0%

Pfizer Inc	36,68	0,5%	4,7%	-6,0%	2,6%	8,4%	1,3%

Amgen Inc	174,83	-0,2%	-0,2%	-10,8%	-1,0%	6,2%	0,5%

Gilead Sciences Inc	73,25	-3,2%	-3,0%	-14,3%	-5,9%	7,4%	2,2%

Vertex Pharmaceuticals Incorpo..	155,15	-5,0%	-6,6%	-8,3%	7,9%	33,4%	3,5%

Astrazeneca PLC ORD SHS $0.25	5.008,00	1,1%	5,2%	-1,7%	-0,8%	6,9%	-2,2%

Novartis AG	76,37	-6,5%	-4,2%	-18,7%	-5,6%	0,0%	-9,0%

Takeda PHARM.CO.LTD.	34,64	-8,5%	-18,5%	-30,4%	-25,5%	-20,1%	-26,0%

Biogen Inc	269,45	0,5%	0,5%	-26,8%	-12,4%	-3,8%	-15,4%

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Instrumenter	Kurs	Ændring
Shire PLC OR..	3.839,00	0,5%
Bristol-Myer..	51,76	0,3%
Johnson & Jo..	126,76	0,5%
Merck & Comp..	59,63	-0,8%
Pfizer Inc	36,68	-1,0%
Amgen Inc	174,83	1,7%	100,27,80,21,20,19,29,42,56,86
Gilead Scien..	73,25	0,7%	49,68,97,1,34,37,48,63,58,71
Vertex Pharm..	155,15	-0,3%	48,68,84,15,27,26,33,29,20,27
Astrazeneca ..	5.008,00	0,3%
Novartis AG	76,37	-0,8%
Takeda PHARM..	34,64	2,3%	100,100,0,0,0,18,18,18,18,18
Biogen Inc	269,45	2,8%	0,87,92,48,63,53,59,61,78,69

Celgene Corporation

Nyheder om Celgene Corporation

Relaterede

Celgene Corporation

Nyheder om Celgene Corporation

Relaterede

Firmaprofil

Peers